Related Experiment Videos

[Digoxin: the results of the DIG study in the XXI century]

Izo Helber1, Paulo J F Tucci

  • 1Escola Paulista de Medicina, Unifesp, São Paulo, SP, Brasil.

Arquivos Brasileiros De Cardiologia
|December 25, 2010
PubMed

Insights

Digoxin

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Context:

  • The DIG study reported no statistical significance in general mortality for digoxin in congestive heart failure (CHF) treatment.
  • This led to a significant decrease in digoxin's use for CHF.
  • However, post hoc analyses highlighted the importance of serum digoxin levels.

Purpose:

  • To re-evaluate the role of digoxin in congestive heart failure (CHF) treatment.
  • To investigate the influence of serum digoxin levels on patient prognosis.
  • To assess the efficacy of digitoxin in an experimental model of CHF.

Summary:

  • Post hoc analyses of the DIG study suggest that digoxin levels below 0.9 ng/ml were associated with decreased mortality and hospitalization in CHF patients.
  • Experimental studies demonstrated prolonged survival in female rats with myocardial infarction-induced CHF treated with digitoxin.
  • These findings indicate that serum digoxin concentration is a critical factor influencing treatment outcomes.

Impact:

  • Re-evaluation of digoxin's therapeutic window in CHF is warranted.
  • Serum digoxin level monitoring may optimize treatment strategies.
  • Further research is needed to clarify digoxin's precise role in managing CHF.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...